Absci Prices $100M Stock Offering with Eli Lilly, Funds Hair-Loss Drug
ABSI has more than doubled off its 52-week low of $2.24.
Summary
Absci announced a $100 million underwritten stock offering, which includes participation from Eli Lilly & Co. and other major financial institutions. This significant capital raise, representing about 8.7% of the company's market cap, will fund the advancement of its lead drug candidate, ABS-201. The offering provides crucial validation and financial runway, especially following the company's Q1 revenue miss. The company also reported positive interim Phase 1 data for ABS-201, its investigational hair-loss treatment, showing a favorable safety profile, which was previously disclosed today.
At the time of this announcement, ABSI was trading at $9.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.24 to $8.57. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.